[{"id":"1394e99e-c38f-44e4-ab4d-aee1d10301bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507541","created_at":"2022-08-19T17:10:01.039Z","updated_at":"2025-02-25T12:28:56.881Z","phase":"Phase 2","brief_title":"TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05507541","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive","tags":["PD-L1 • ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-24"},{"id":"49601ae5-fd50-4ceb-b7f3-e357f9864917","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922724","created_at":"2021-01-18T19:17:55.581Z","updated_at":"2025-02-25T12:27:11.116Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03922724","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • HLA-B • HLA-C","pipe":" | ","alterations":" ALK positive","tags":["ALK • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • sirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-24"},{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"1a7e9bb9-7b86-4b0f-bf52-ec51de4a9d98","acronym":"P30CA033572","url":"https://clinicaltrials.gov/study/NCT03113500","created_at":"2021-01-18T15:20:28.612Z","updated_at":"2025-02-25T14:01:16.731Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT03113500 - P30CA033572","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 05/25/2017","start_date":" 05/25/2017","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2025-02-19"},{"id":"bbff33d0-fbb7-447e-b61a-196b5c2984ea","acronym":"ALTA-3","url":"https://clinicaltrials.gov/study/NCT03596866","created_at":"2021-01-18T17:41:06.342Z","updated_at":"2025-02-25T14:07:13.042Z","phase":"Phase 3","brief_title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT03596866 - ALTA-3","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-19"},{"id":"52814cd1-a8ab-4fbc-9958-b65faef07451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05599412","created_at":"2022-10-31T13:56:49.808Z","updated_at":"2025-02-25T14:41:38.018Z","phase":"","brief_title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","source_id_and_acronym":"NCT05599412","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-02-14"},{"id":"b9dc9326-f8bf-456a-84d5-8c844765d88e","acronym":"M23-647","url":"https://clinicaltrials.gov/study/NCT05753501","created_at":"2023-03-03T15:01:38.988Z","updated_at":"2025-02-25T14:41:53.479Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","source_id_and_acronym":"NCT05753501 - M23-647","lead_sponsor":"AbbVie","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABBV-101"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"},{"id":"393ae514-083b-4a6f-a6c0-c472fe56deef","acronym":"KEYNOTE-E59","url":"https://clinicaltrials.gov/study/NCT05083481","created_at":"2021-10-19T15:58:03.788Z","updated_at":"2025-02-25T15:19:18.701Z","phase":"Phase 1/2","brief_title":"A Study of ASP1570 Alone or in Combination With Pembrolizumab or Standard Therapies in Adults With Solid Tumors","source_id_and_acronym":"NCT05083481 - KEYNOTE-E59","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion","tags":["EGFR • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK positive • ALK mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • docetaxel • Lonsurf (trifluridine/tipiracil) • ASP1570"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 10/19/2021","start_date":" 10/19/2021","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-12"},{"id":"458cb283-b41f-46c8-9cf0-1513a2f0ecd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01828112","created_at":"2021-01-17T17:22:24.644Z","updated_at":"2025-02-25T16:36:14.568Z","phase":"Phase 3","brief_title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","source_id_and_acronym":"NCT01828112","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • docetaxel • Zykadia (ceritinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 01/26/2016","primary_completion_date":" 01/26/2016","study_txt":" Completion: 11/10/2023","study_completion_date":" 11/10/2023","last_update_posted":"2025-02-07"},{"id":"9581c2d9-b454-4592-b3f9-10aa36b40702","acronym":"ANVIL","url":"https://clinicaltrials.gov/study/NCT02595944","created_at":"2021-01-18T12:36:00.436Z","updated_at":"2025-02-25T16:43:58.258Z","phase":"Phase 3","brief_title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","source_id_and_acronym":"NCT02595944 - ANVIL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 903","initiation":"Initiation: 07/22/2016","start_date":" 07/22/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e6ddbe9a-bb3f-4f95-a33c-1e9db3a4644c","acronym":"ALINA","url":"https://clinicaltrials.gov/study/NCT03456076","created_at":"2021-01-18T17:02:25.362Z","updated_at":"2025-02-25T16:44:20.606Z","phase":"Phase 3","brief_title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03456076 - ALINA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 06/26/2023","primary_completion_date":" 06/26/2023","study_txt":" Completion: 11/19/2026","study_completion_date":" 11/19/2026","last_update_posted":"2025-02-05"},{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2025-02-25T16:07:00.519Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-22"},{"id":"a7d87c22-61ed-4880-930a-7f94876963f9","acronym":"KEYNOTE-E64","url":"https://clinicaltrials.gov/study/NCT04787042","created_at":"2021-03-08T12:53:50.679Z","updated_at":"2025-02-25T16:11:14.799Z","phase":"Phase 1/2","brief_title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","source_id_and_acronym":"NCT04787042 - KEYNOTE-E64","lead_sponsor":"Simcha IL-18, Inc.","biomarkers":" ALK • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • ALK positive • ALK mutation","tags":["ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)"],"overall_status":"Recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-15"},{"id":"50e95443-c92c-48dc-b638-e94294dd906a","acronym":"KEYNOTE-A72","url":"https://clinicaltrials.gov/study/NCT03260322","created_at":"2021-01-18T16:06:27.240Z","updated_at":"2025-02-25T16:06:46.737Z","phase":"Phase 1","brief_title":"A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03260322 - KEYNOTE-A72","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP8374"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2024-11-13"},{"id":"cc0e252d-323c-463e-9f6b-bb8fa47915a5","acronym":"KEYNOTE-A87","url":"https://clinicaltrials.gov/study/NCT03565445","created_at":"2021-01-18T17:32:45.491Z","updated_at":"2025-02-25T16:08:02.730Z","phase":"Phase 1","brief_title":"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03565445 - KEYNOTE-A87","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 03/27/2023","study_completion_date":" 03/27/2023","last_update_posted":"2024-11-01"},{"id":"93d233c8-d3b1-4a92-8fd5-b306320c34dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586999","created_at":"2021-01-18T17:38:33.204Z","updated_at":"2025-02-25T14:27:16.447Z","phase":"Phase 1/2","brief_title":"Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas","source_id_and_acronym":"NCT03586999","lead_sponsor":"University of Colorado, Denver","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisolone"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 05/26/2021","primary_completion_date":" 05/26/2021","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2024-10-29"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"02e83317-1e46-4ec1-8ee3-e88e0be802c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02321501","created_at":"2021-01-18T11:00:33.247Z","updated_at":"2024-07-02T16:34:27.615Z","phase":"Phase 1","brief_title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02321501","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-10"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"72f7e625-8a17-4823-ab2b-fcbb2d97c51f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05014464","created_at":"2021-08-20T14:52:58.520Z","updated_at":"2024-07-02T16:34:59.693Z","phase":"","brief_title":"ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma","source_id_and_acronym":"NCT05014464","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 08/08/2027","study_completion_date":" 08/08/2027","last_update_posted":"2024-05-31"},{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"820375fa-d648-40c6-bb10-439713fd0a5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04997382","created_at":"2021-08-09T13:53:18.245Z","updated_at":"2024-07-02T16:35:01.224Z","phase":"Phase 2","brief_title":"Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC","source_id_and_acronym":"NCT04997382","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Alecensa (alectinib)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 08/17/2021","start_date":" 08/17/2021","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2024-05-24"},{"id":"84516b21-8265-457c-a480-fa67aca332aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04837196","created_at":"2021-04-08T12:52:25.748Z","updated_at":"2024-07-02T16:35:01.857Z","phase":"Phase 1/2","brief_title":"Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen","source_id_and_acronym":"NCT04837196","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • BRAF • ALK • WT1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • BRAF • ALK • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ASP7517"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-23"}]